700 likes | 823 Vues
IRCCS Ospedale San Raffaele Milano Università Vita-Salute San Raffaele. Pharmacological pre-emptive strategies for cardiac surgery : give me the magic bullet , please. INTERCEPT 2009 S Donato Milanese, Milan, April 17h 2009. Speaker: Landoni G.
E N D
IRCCS Ospedale San Raffaele Milano Università Vita-Salute San Raffaele Pharmacologicalpre-emptivestrategiesforcardiacsurgery: give me the magicbullet, please INTERCEPT 2009 S Donato Milanese, Milan, April 17h 2009 Speaker: Landoni G
MAGIC BULLETS TO REDUCE MORTALITY IN CARDIAC SURGERY • THERE ARE NO GUIDELINES • THERE IS NO CONSENSUS CONFERENCE • THERE IS NO LARGE RANDOMIZED CONTROLLED STUDY ADEQUATELY POWERED TO SUGGEST A REDUCTION IN MORTALITY
AN OVERVIEW OF META-ANALYSIS • PEXELIZUMAB • LEVOSIMENDAN • FENOLDOPAM • VOLATILE AGENTS (Intercept 2006)
MAGIC BULLET PEXELIZUMAB LEVOSIMENDAN FENOLDOPAM VOLATILE AGENTS NNT TO PREVENT ONE DEATH 100 12 19 or 26 84 AN OVERVIEW OF META-ANALYSIS
Description of the ten studies included in the meta-analysis. * CABG: coronary artery bypass graft † CPB: cardiopulmonary bypass ‡ OPCABG: off-pump coronary artery bypass graft
Number of patients and interventions of included studies. † CPB: cardiopulmonary bypass # LCOS: low cardiac output syndrome
Levosimendan and Mortality in Cardiac Surgery • 11/235=4.7% v 26/205=12.7% • P=0.007 • NNT = 12
Evidence! LEVOSIMENDAN VS CONTROLMyocardial Infarction in cardiac surgery • 2/183=1.1% v 9/153=5.9% • P=0.04
VOLATILE ANESTHETICS FENOLDOPAM DESMOPRESSIN ESMOLOL LEVOSIMENDAN VALVOLE PERCUTANEE landoni.giovanni@hsr.it www.itacta.org 4 200 AIFA 2006 34 1.000 MINISTRY 2008 3 200 3 200 10 1.000 3 150 ITACTA ONGOING RCTsTOPICS HOSPITALS PATIENTS GRANTS
AIM OF THE STUDY To evaluate the renoprotective action of fenoldopam in a selected high-risk group of patients undergoing cardiac surgery
RESULTS • Post-operative data
Fenoldopam and Death in Critically ill patients 81/487(17%) versus 109/531 (21%) p=0.01 NNT=26
Pooled estimates of risk for need for renal replacement therapy 34/526 (6%) versus 59/570 (10%) p=0.007 NNT=26
Fenoldopam and Death in Cardiovascular Surgery 28/503 (6%) versus 55/503 (11%) p=0.002 NNT=19
Fenoldopam and renal replacement therapy in cardiovascular surgery 30/528 (6%) versus 71/531 (13%) p<0.001 NNT=13
VOLATILE ANESTHETICS FENOLDOPAM DESMOPRESSIN ESMOLOL LEVOSIMENDAN VALVOLE PERCUTANEE landoni.giovanni@hsr.it www.itacta.org 4 200 AIFA 2006 34 1.000 MINISTRY 2008 3 200 3 200 10 1.000 3 150 ITACTA ONGOING RCTsTOPICS HOSPITALS PATIENTS GRANTS
FENO-HSR FENOLDOPAM E INSUFFICIENZA RENALE
DESIGN • Fenoldopam vs placebo • randomized • double blind • multicenter (32 centers, 1000 patients)
Which patients? “R” (RIFLE) after cardiac surgery Serum creatinine increase by 50% or Urinary output <0,5 ml/kg/h for 6 h Planned ICU stay > 24 hours
AIM OF THE STUDY Reduction of the need for renal replacement therapy From 10% to 5%
META-ANALYSIS(cardiac anaesthesia) • 22 randomized studies (15 CPB-CABG; 6 OP-CABG; 1 mitral valve surgery) • 1922 patients (904 TIVA and 1018 DES or SEVO) • 16 studies administered volatile anesthetics throughout all the procedure (6 studies for 5-30 minutes)
Evidence! Mortality
Evidence! Mortality • 4/977=0.4% v 14/872=1.6% • NNT=84 • RRR=(1,6-0,4)/1,6=75% • OR: 0.31(0.12-0.80) • P=0.02
Evidence! Myocardial infarction
Evidence! Myocardial infarction • 24/979=2.4% v 45/874=5.1% • NNT=37 • RRR: (5.1-2.4)/5.1 = 53% • OR: 0.51(0.32-0.84) • p=0.008